Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab

Omalizumab is a treatment for asthma that has a success rate of approximately 40% to 50%.1 Recent mechanistic studies have suggested that basophil behavior may explain some of the variability in response to therapy. First, the biological changes that occur during treatment with omalizumab have suggested that changes in basophil IgE-mediated reactivity occur faster than changes in the mast cell response.2,3 Other studies have shown that the IgE-mediated response of basophils results largely from limitations in the expression of the early required tyrosine kinase syk.

http://ift.tt/2mN4aei